RxDoctor Payments Data

Donald Canaday, MD

Interventional Cardiology · Spokane, WANPI 1255380788

Payments from drug & device makers

$730in general payments, 2019–2025

Across 29 payments — averaging $25.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$259
  • AstraZeneca$87
  • Abbott$75
  • Sanofi-aventis U.S. LLC$58
  • Pfizer$55
  • Bayer$50
  • plus $147 from 5 others

What the payments were for

  • Food & beverage$64388%
  • Education$8712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$730 in reported general payments places this provider in the 20th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$49,375
Medicare patients
210
Services billed
477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$155,069
XareltoRivaroxaban47$61,253
EntrestoSacubitril/Valsartan49$42,221
Repatha SureclickEvolocumab58$31,822
Repatha SyringeEvolocumab16$14,444
JardianceEmpagliflozin13$11,237
Praluent PenAlirocumab19$8,261
Metoprolol Succinate246$4,241
Rosuvastatin Calcium179$2,056
Losartan Potassium119$1,215
Potassium Chloride72$1,049
Atorvastatin Calcium82$970
Isosorbide Mononitrate ErIsosorbide Mononitrate34$758
Nebivolol Hcl18$758
Carvedilol75$754

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$55$155,069164 claims
NovartisEntresto$259$42,22149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →